- Home
- SYRE vs XOMAP Comparison
SYRE vs XOMAP Comparison
Compare SYRE & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRE
- XOMAP
- Stock Information
- Founded
- SYRE 2013
- XOMAP N/A
- Country
- SYRE United States
- XOMAP United States
- Employees
- SYRE N/A
- XOMAP 13
- Industry
- SYRE Biotechnology: Pharmaceutical Preparations
- XOMAP Biotechnology: Pharmaceutical Preparations
- Sector
- SYRE Health Care
- XOMAP Health Care
- Exchange
- SYRE Nasdaq
- XOMAP Nasdaq
- Market Cap
- SYRE N/A
- XOMAP N/A
- IPO Year
- SYRE 2016
- XOMAP N/A
- Fundamental
- Price
- SYRE $23.70
- XOMAP $25.91
- Analyst Decision
- SYRE Strong Buy
- XOMAP
- Analyst Count
- SYRE 8
- XOMAP 0
- Target Price
- SYRE $51.50
- XOMAP N/A
- AVG Volume (30 Days)
- SYRE 600.7K
- XOMAP N/A
- Earning Date
- SYRE 02-27-2025
- XOMAP N/A
- Dividend Yield
- SYRE N/A
- XOMAP N/A
- EPS Growth
- SYRE N/A
- XOMAP N/A
- EPS
- SYRE N/A
- XOMAP N/A
- Revenue
- SYRE N/A
- XOMAP N/A
- Revenue This Year
- SYRE $168.62
- XOMAP N/A
- Revenue Next Year
- SYRE $47.61
- XOMAP N/A
- P/E Ratio
- SYRE N/A
- XOMAP N/A
- Revenue Growth
- SYRE N/A
- XOMAP N/A
- 52 Week Low
- SYRE $20.07
- XOMAP N/A
- 52 Week High
- SYRE $47.97
- XOMAP N/A
- Technical
- Relative Strength Index (RSI)
- SYRE 54.71
- XOMAP 56.05
- Support Level
- SYRE $21.67
- XOMAP $25.52
- Resistance Level
- SYRE $22.81
- XOMAP $25.70
- Average True Range (ATR)
- SYRE 1.42
- XOMAP 0.11
- MACD
- SYRE 0.40
- XOMAP 0.04
- Stochastic Oscillator
- SYRE 96.23
- XOMAP 91.37
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.